Abstract
Food allergy (FA) is an increasingly prevalent global health problem.1 Previously, the only management for FA was the avoidance of food allergens. However, oral immunotherapy (OIT) has become increasingly popular as a potential treatment option for FA.2,3 Recently, a product for peanut OIT, Palforzia (Aimmune Therapeutics, Brisbane, Calif), was approved by the US Food and Drug Administration for use in children aged 4 to 17 years. OIT involves the continued daily consumption of a progressively escalating dose of food allergen, which can induce a state of desensitization or tolerance in patients with FA after a maintenance period ranging from months to years.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
